<?xml version="1.0" encoding="UTF-8"?>
<p>We used the deterministic model, described in the previous section, to infer the proportion of people with protective immunity within each age group at the end of the 2016 epidemic 
 <inline-formula id="pntd.0007978.e010">
  <alternatives>
   <graphic xlink:href="pntd.0007978.e010.jpg" id="pntd.0007978.e010g" mimetype="image" position="anchor" orientation="portrait" xmlns:xlink="http://www.w3.org/1999/xlink"/>
   <math id="M10">
    <msub>
     <mover accent="true">
      <mi>p</mi>
      <mo>˜</mo>
     </mover>
     <mi>a</mi>
    </msub>
   </math>
  </alternatives>
 </inline-formula>. We used one thousand posterior samples of 
 <inline-formula id="pntd.0007978.e011">
  <alternatives>
   <graphic xlink:href="pntd.0007978.e011.jpg" id="pntd.0007978.e011g" mimetype="image" position="anchor" orientation="portrait" xmlns:xlink="http://www.w3.org/1999/xlink"/>
   <math id="M11">
    <msub>
     <mover accent="true">
      <mi>p</mi>
      <mo>˜</mo>
     </mover>
     <mi>a</mi>
    </msub>
   </math>
  </alternatives>
 </inline-formula> in the ABM to allow the propagation of uncertainty. Protective immunity to ZIKV after infection was lifelong in our first scenario, so the reduction of the overall proportion of immune individuals in the population decreased only because of population renewal. Given the absence of evidence about the duration of immunity to ZIKV, we considered four scenarios assuming exponentially distributed durations of immunity with means of 15, 30, 60, 90, or 150 years. These values correspond to a proportion of initially immune agents that loses immunity after 10 years of 55%, 28%, 15%, 11% or 6%, respectively (Supporting information S1).
</p>
